. 2020 Oct 15;12(10):6584–6598.

Table 6.

Treatment-related adverse events

Items	Apatinib					Apatinib plus cTACE					Apatinib plus DEB-TACE					P value^*	P value^#	P value^&	P value^†

	Total	I	II	III	IV	Total	I	II	III	IV	Total	I	II	III	IV
Fatigue, No. (%)	6 (60.0)	4 (40.0)	1 (10.0)	1 (10.0)	0 (0.0)	7 (58.3)	4 (33.3)	2 (16.7)	1 (8.3)	0 (0.0)	8 (61.5)	5 (38.5)	2 (15.4)	1 (7.7)	0 (0.0)	0.987	0.870	0.940	0.937
Anorexia, No. (%)	3 (30.0)	2 (20.0)	1 (10.0)	0 (0.0)	0 (0.0)	5 (41.7)	3 (25.0)	2 (16.7)	0 (0.0)	0 (0.0)	5 (38.5)	4 (30.8)	1 (7.7)	0 (0.0)	0 (0.0)	0.846	0.870	0.673	0.571
Vomiting, No. (%)	1 (10.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	8 (66.7)	4 (33.3)	3 (25.0)	1 (8.3)	0 (0.0)	7 (53.8)	3 (23.1)	3 (23.1)	1 (7.7)	0 (0.0)	0.022	0.513	0.029	0.011
Diarrhea, No. (%)	1 (10.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (15.4)	2 (15.4)	0 (0.0)	0 (0.0)	0 (0.0)	0.846	0.588	0.704	0.892
Hoarseness, No. (%)	3 (30.0)	3 (30.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (25.0)	3 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (23.1)	2 (15.4)	1 (7.7)	0 (0.0)	0 (0.0)	0.929	0.910	0.708	0.793
Hypertension, No. (%)	8 (80.0)	2 (20.0)	4 (40.0)	2 (20.0)	0 (0.0)	11 (91.7)	3 (25.0)	4 (33.3)	4 (33.3)	0 (0.0)	12 (92.3)	3 (23.1)	5 (38.5)	4 (30.8)	0 (0.0)	0.601	0.953	0.385	0.427
Hand-foot syndrome, No. (%)	8 (80.0)	4 (40.0)	2 (20.0)	2 (20.0)	0 (0.0)	8 (66.7)	3 (25.0)	2 (16.7)	3 (25.0)	0 (0.0)	10 (76.9)	4 (30.8)	3 (23.1)	3 (23.1)	0 (0.0)	0.747	0.568	0.859	0.484
Mucositis, No. (%)	4 (40.0)	3 (30.0)	1 (10.0)	0 (0.0)	0 (0.0)	4 (33.3)	3 (25.0)	1 (8.3)	0 (0.0)	0 (0.0)	3 (23.1)	2 (15.4)	1 (7.7)	0 (0.0)	0 (0.0)	0.676	0.568	0.382	0.746
Proteinuria, No. (%)	6 (60.0)	4 (40.0)	1 (10.0)	1 (10.0)	0 (0.0)	7 (58.3)	6 (50.0)	0 (0.0)	1 (8.3)	0 (0.0)	12 (92.3)	10 (76.9)	2 (15.4)	0 (0.0)	0 (0.0)	0.109	0.073	0.127	0.937
Hypoproteinemia, No. (%)	8 (80.0)	6 (60.0)	2 (20.0)	0 (0.0)	0 (0.0)	11 (91.7)	6 (50.0)	5 (41.7)	0 (0.0)	0 (0.0)	13 (100.0)	10 (76.9)	3 (23.1)	0 (0.0)	0 (0.0)	0.236	0.288	0.178	0.427
Hyperbilirubinemia, No. (%)	5 (50.0)	2 (20.0)	1 (10.0)	2 (20.0)	0 (0.0)	11 (91.7)	3 (25.0)	6 (50.0)	2 (16.7)	0 (0.0)	10 (76.9)	7 (53.8)	0 (0.0)	3 (23.1)	0 (0.0)	0.081	0.315	0.179	0.056
ALT increased, No. (%)	7 (70.0)	5 (50.0)	1 (10.0)	1 (10.0)	0 (0.0)	12 (100.0)	4 (33.3)	5 (41.7)	3 (25.0)	0 (0.0)	12 (92.3)	4 (30.8)	4 (30.8)	4 (30.8)	0 (0.0)	0.077	0.327	0.162	0.078
AST increased, No. (%)	7 (70.0)	4 (40.0)	2 (20.0)	1 (10.0)	0 (0.0)	12 (100.0)	4 (33.3)	4 (33.3)	4 (33.3)	0 (0.0)	13 (100.0)	2 (15.4)	6 (46.2)	4 (30.8)	1 (7.7)	0.017	1.000	0.034	0.041
Anemia, No. (%)	3 (30.0)	2 (20.0)	1 (10.0)	0 (0.0)	0 (0.0)	12 (100.0)	7 (58.3)	4 (33.3)	1 (8.3)	0 (0.0)	11 (84.6)	6 (46.2)	5 (38.5)	0 (0.0)	0 (0.0)	0.001	0.157	0.013	0.001
Neutropenia, No. (%)	2 (20.0)	0 (0.0)	1 (10.0)	1 (10.0)	0 (0.0)	9 (75.0)	2 (16.7)	4 (33.3)	1 (8.3)	2 (16.7)	7 (53.8)	4 (30.8)	2 (15.4)	1 (7.7)	0 (0.0)	0.036	0.271	0.099	0.030
Thrombocytopenia, No. (%)	3 (30.0)	1 (10.0)	0 (0.0)	2 (20.0)	0 (0.0)	9 (75.0)	3 (25.0)	4 (33.3)	2 (16.7)	0 (0.0)	7 (53.8)	4 (30.8)	0 (0.0)	3 (23.1)	0 (0.0)	0.108	0.271	0.253	0.084

Comparison was determined by Chi-square test or Fisher’s exact test.

total adverse events comparison among 3 groups.

total adverse events: Apatinib plus DEB-TACE vs. Apatinib plus cTACE.

total adverse events: Apatinib plus DEB-TACE vs. Apatinib.

^†

total adverse events: Apatinib plus cTACE vs. Apatinib.

cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; ALT, alanine transaminase; AST, aspartate transaminase.